Previous clinical trials combining MEK inhibitor with anti-PD-L1 in solid tumors (melanoma, NSCLC, and colorectal cancers) show a manageable safety profile, but with only moderate tumor response13–15. This evidence concerns the gene CD274 and neoplasm.